2. Search Result
Search Result
Results for "

neutral antagonist

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-105689
    AGN 192870

    		RAR/RXR Others
    AGN 192870 is a RAR neutral antagonist with Kds of 147, 33, and 42 nM for RARα, RARβ, and RARγ, respectively. AGN 192870 shows IC50s of 87 and 32 nM for RARαand RARγ, respectively. AGN 192870 shows RARβ partial agonism . AGN 192870 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    AGN 192870
  • HY-101259
    BMS-195614

    BMS 614

    		 RAR/RXR Cancer
    BMS-195614 (BMS 614) is a neutral RARα-selective antagonist with a Ki of 2.5 nM .
    BMS-195614
  • HY-110206
    AM6545

    		Cannabinoid Receptor Metabolic Disease
    AM6545 is a peripherally active, cannabinoid receptor antagonist with limited brain penetration. AM6545 binds to CB1 and CB2 receptors with Kis of 1.7 nM and 523 nM, respectively. AM6545 is a neutral antagonist. AM6545 can be used for the research of obesity and its complications .
    AM6545
  • HY-107556
    VUF 5681 dihydrobromide

    		Histamine Receptor Neurological Disease
    VUF 5681 dihydrobromide is a neutral antagonist of histamine H3 receptor. VUF 5681 dihydrobromide also has partial agonist function of H3 receptor. VUF 5681 dihydrobromide blocks the effects of Thioperamide (HY-12206). VUF 5681 dihydrobromide is used in central nervous system disease research .
    VUF 5681 dihydrobromide
  • HY-121545
    CB-52

    		Cannabinoid Receptor Inflammation/Immunology
    CB-52 is the ligand and neutral antagonist of CB2 cannabinoid receptor .
    CB-52
  • HY-162682
    5-HT6R antagonist 4

    		5-HT Receptor Neurological Disease
    5-HT6R antagonist 4 (compound 30) is a neutral antagonist of 5-HT6R, with the Ki of 1 nM .
    5-HT6R antagonist 4
  • HY-133533
    O-2050

    		Cannabinoid Receptor Neurological Disease
    O-2050 is a high affinity cannabinoid CB1 receptor antagonist with a Ki of 2.5 nM. O-2050 inhibits cannabinoid CB2 receptor (Ki=0.2 nM). O-2050 can cause locomotor stimulation in mice .
    O-2050
  • HY-107557
    Proxyfan

    		Histamine Receptor Neurological Disease
    Proxyfan is a potent histamine H3 receptor antagonist with Ki values of 2.9 nM and 2.7 nM for rat and human H3 receptor, respectively. Proxyfan is over 1000-fold more potent at H3 receptors than other histamine receptors .
    Proxyfan
  • HY-107557A
    Proxyfan Oxalate

    		Histamine Receptor Neurological Disease
    Proxyfan Oxalate is a potent histamine H3 receptor antagonist with Ki values of 2.9 nM and 2.7 nM for rat and human H3 receptor, respectively. Proxyfan Oxalate is over 1000-fold more potent at H3 receptors than other histamine receptors .
    Proxyfan Oxalate
  • HY-110020
    rel-O-2050

    		Cannabinoid Receptor Metabolic Disease
    rel-O-2050 (Compound O-2050) is a neutral cannabinoid CB1 receptor antagonist. rel-O-2050 also decreases food intake in mice .
    rel-O-2050
  • HY-121827
    LH21

    		Cannabinoid Receptor Metabolic Disease
    LH-21 is a potent in vivo neutral cannabinoid CB1 receptor antagonist. LH-21 reduces food intake and body weight gain in obese Zucker rats. , and displays efficacy as a feeding inhibitor .
    LH21
  • HY-107562
    JNJ 10181457 dihydrochloride

    		Histamine Receptor Neurological Disease
    JNJ-10181457 is a neutral, potent, brain-penetrant and selective non-imidazole H3 antagonist which increases NE and ACh concentrations in rat frontal cortex. JNJ-10181457 can be used for neurological research .
    JNJ 10181457 dihydrochloride
  • HY-15043
    ELN-441958

    		Bradykinin Receptor Inflammation/Immunology Endocrinology
    ELN-441958 is a potent, neutral, competitive and selective bradykinin B1 receptor antagonist with a Ki of 0.26 nM against native human bradykinin B1 receptor. ELN-441958 has high oral bioavailability, and has low CNS exposure in the mouse .
    ELN-441958
  • HY-111241
    SV 293

    		Others Neurological Disease
    SV 293 is a selective antagonist with neutral antagonist activity. SV 293 binds to human D2 receptors with 100-fold higher affinity and has lower affinity for human D3 and D4 dopamine receptor subtypes. SV 293 was found to block the effects of the full agonist quinpirole in forskolin-dependent adenylate acylase inhibition assays and electrophysiological assays. SV 293 can be used as a useful pharmacological tool to study the role of dopamine D2-like receptor subtypes in dopamine pathways associated with neurological, neuropsychiatric and movement disorders .
    SV 293

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: